Use of Plasma in the Management of Central Nervous System Bleeding: Evidence-Based Consensus Recommendations
- 14 December 2013
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 31 (1) , 66-90
Abstract
Central nervous system (CNS) hemorrhage is a potentially life-threatening condition, especially in patients with acquired coagulopathy. In this setting, treatment of CNS bleeding includes hemostatic therapy to replenish coagulation factors. There is currently a debate over the hemostatic efficacy of plasma in many clinical settings, alongside increasing concern about transfusion-associated adverse events. Despite these concerns, plasma is widely used. Moreover, plasma transfusion practice is variable and there is currently no uniform approach to treatment of traumatic, surgical or spontaneous CNS hemorrhage. This study addresses the need for guidance on the indications and potential risks of plasma transfusion in these settings. An Expert Consensus Panel was convened to develop recommendations guiding the use of plasma to treat bleeding and/or coagulopathy associated with CNS hemorrhage. The panel did not advise on the best treatment available but rather proposed recommendations to be used in the formulation of local procedures to support emergency physicians in their decision-making process. Evidence was systematically gathered from the literature and rated using methods established by the Scottish Intercollegiate Guidelines Network. The evidence was used to develop graded consensus recommendations, which are presented along with the evidence-based rationale for each in this report. Sixty-five articles were identified covering both vitamin K antagonist-anticoagulation reversal and treatment of bleeding/coagulopathy in non-anticoagulated patients. Recommendations were then developed in four clinical scenarios within each area, and agreed on unanimously by all members of the panel. The Panel considered plasma to be reasonable therapy for CNS hemorrhage requiring urgent correction of coagulopathy, although physicians should be prepared for potential cardiopulmonary complications, and evidence suggests that alternative therapies have superior risk–benefit profiles. Plasma could not be recommended in the absence of hemorrhage or coagulopathy. Consideration of the absolute risks and benefits of plasma therapy before transfusion is imperative.Keywords
This publication has 75 references indexed in Scilit:
- Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trialBMJ, 2012
- Adverse effects of plasma transfusionTransfusion, 2012
- Early and individualized goal-directed therapy for trauma-induced coagulopathyScandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2012
- Intracranial HemorrhageAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Treatments for reversing warfarin anticoagulation in patients with acute intracranial hemorrhage: a structured literature reviewInternational Journal of Emergency Medicine, 2011
- The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trialThe Lancet, 2011
- Emotional or evidence-based medicine: is there a moral tragedy in haemostatic therapy?Critical Care, 2011
- Incidence and transfusion risk factors for transfusion‐associated circulatory overload among medical intensive care unit patientsTransfusion, 2010
- Intracranial bleeding in patients with traumatic brain injury: A prognostic studyBMC Emergency Medicine, 2009
- The Challenge of Designing a Treatment Trial for Warfarin-Associated Intracerebral HemorrhageStroke, 2009